Guggenheim downgraded SpringWorks Therapeutics (SWTX) to Neutral from Buy after the company and Merck KGaA (MKKGY) announced a definitive agreement for Merck KGaA to acquire SpringWorks for $47 per share in cash.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- Amazon sellers pull away from Prime Day, IBM to invest in U.S.: Morning Buzz
- Piper says SpringWorks deal suggests Immunome’s varegacestat ‘undervalued’
- SpringWorks Therapeutics downgraded to In Line from Outperform at Evercore ISI
- SpringWorks Therapeutics downgraded to Equal Weight from Overweight at Barclays
- SpringWorks Therapeutics downgraded to Neutral from Outperform at Wedbush